Michael Schmitz
Stock Analyst at Guggenheim
(2.83)
# 1,836
Out of 5,056 analysts
11
Total ratings
87.5%
Success rate
16.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Maintains: Buy | $3 → $5 | $2.86 | +74.83% | 1 | Nov 14, 2025 | |
| MRSN Mersana Therapeutics | Downgrades: Neutral | n/a | $27.54 | - | 1 | Nov 14, 2025 | |
| MRUS Merus | Downgrades: Neutral | $109 → $97 | $95.80 | +1.25% | 3 | Sep 30, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $30.32 | +41.82% | 1 | Sep 24, 2025 | |
| EXEL Exelixis | Reiterates: Buy | $45 | $42.65 | +5.51% | 1 | Jul 29, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $70.58 | +16.18% | 2 | Oct 28, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $12.99 | +207.93% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.02 | - | 1 | Jan 3, 2023 |
Erasca
Nov 14, 2025
Maintains: Buy
Price Target: $3 → $5
Current: $2.86
Upside: +74.83%
Mersana Therapeutics
Nov 14, 2025
Downgrades: Neutral
Price Target: n/a
Current: $27.54
Upside: -
Merus
Sep 30, 2025
Downgrades: Neutral
Price Target: $109 → $97
Current: $95.80
Upside: +1.25%
Genmab
Sep 24, 2025
Upgrades: Buy
Price Target: $43
Current: $30.32
Upside: +41.82%
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $42.65
Upside: +5.51%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $70.58
Upside: +16.18%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $12.99
Upside: +207.93%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.02
Upside: -